Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection
In this study, we evaluated the effectiveness of the bivalent mRNA COVID-19 vaccines against the Omicron variant in individuals with or without prior SARS-CoV-2 infection history. We assessed the SARS-CoV-2-specific neutralizing antibody in serum samples by surrogate virus neutralizing assay (sVNT)...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/15/8/1756 |
| _version_ | 1797583030064250880 |
|---|---|
| author | Kristin Widyasari Jieun Jang Taejoon Kang Sunjoo Kim |
| author_facet | Kristin Widyasari Jieun Jang Taejoon Kang Sunjoo Kim |
| author_sort | Kristin Widyasari |
| collection | DOAJ |
| description | In this study, we evaluated the effectiveness of the bivalent mRNA COVID-19 vaccines against the Omicron variant in individuals with or without prior SARS-CoV-2 infection history. We assessed the SARS-CoV-2-specific neutralizing antibody in serum samples by surrogate virus neutralizing assay (sVNT) and determined the serum’s neutralizing capacity against the Omicron BA.5 by a plaque reduction neutralizing test (PRNT50). The results of the sVNT assay demonstrate a higher percentage of inhibition of the serum samples from the infected group than from the uninfected group (<i>p</i> = 0.01) before the bivalent vaccination but a similarly high percentage of inhibition after the vaccination. Furthermore, the results of the PRNT50 assay demonstrate a higher neutralizing capacity of the serum samples against Omicron BA.5 in the infected group compared to the uninfected group, both before and after the bivalent vaccine administration (<i>p</i> < 0.01 and <i>p</i> = 0.02 for samples collected before and after the bivalent vaccination, respectively). A higher neutralizing capacity of the serum samples against BA.5 following bivalent vaccination compared to those before vaccination suggests the efficacy of bivalent mRNA COVID-19 vaccines in triggering an immune response against the Omicron variant, particularly BA.5, regardless of infection history. |
| first_indexed | 2024-03-10T23:31:03Z |
| format | Article |
| id | doaj.art-c748285968ee4eeaa0a3c003583320dd |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T23:31:03Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-c748285968ee4eeaa0a3c003583320dd2023-11-19T03:21:23ZengMDPI AGViruses1999-49152023-08-01158175610.3390/v15081756Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 InfectionKristin Widyasari0Jieun Jang1Taejoon Kang2Sunjoo Kim3Gyeongsang Institute of Health Sciences, Gyeongsang National University, Jinju 52727, Republic of KoreaGyeongnam Center for Infectious Disease Control and Prevention, Changwon 51154, Republic of KoreaBionanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejon 34141, Republic of KoreaGyeongsang Institute of Health Sciences, Gyeongsang National University, Jinju 52727, Republic of KoreaIn this study, we evaluated the effectiveness of the bivalent mRNA COVID-19 vaccines against the Omicron variant in individuals with or without prior SARS-CoV-2 infection history. We assessed the SARS-CoV-2-specific neutralizing antibody in serum samples by surrogate virus neutralizing assay (sVNT) and determined the serum’s neutralizing capacity against the Omicron BA.5 by a plaque reduction neutralizing test (PRNT50). The results of the sVNT assay demonstrate a higher percentage of inhibition of the serum samples from the infected group than from the uninfected group (<i>p</i> = 0.01) before the bivalent vaccination but a similarly high percentage of inhibition after the vaccination. Furthermore, the results of the PRNT50 assay demonstrate a higher neutralizing capacity of the serum samples against Omicron BA.5 in the infected group compared to the uninfected group, both before and after the bivalent vaccine administration (<i>p</i> < 0.01 and <i>p</i> = 0.02 for samples collected before and after the bivalent vaccination, respectively). A higher neutralizing capacity of the serum samples against BA.5 following bivalent vaccination compared to those before vaccination suggests the efficacy of bivalent mRNA COVID-19 vaccines in triggering an immune response against the Omicron variant, particularly BA.5, regardless of infection history.https://www.mdpi.com/1999-4915/15/8/1756SARS-CoV-2COVID-19bivalent mRNA vaccineneutralizing antibodyOmicron variant |
| spellingShingle | Kristin Widyasari Jieun Jang Taejoon Kang Sunjoo Kim Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection Viruses SARS-CoV-2 COVID-19 bivalent mRNA vaccine neutralizing antibody Omicron variant |
| title | Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection |
| title_full | Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection |
| title_fullStr | Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection |
| title_full_unstemmed | Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection |
| title_short | Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection |
| title_sort | effectiveness of bivalent omicron containing booster vaccines against sars cov 2 omicron variant among individuals with and without prior sars cov 2 infection |
| topic | SARS-CoV-2 COVID-19 bivalent mRNA vaccine neutralizing antibody Omicron variant |
| url | https://www.mdpi.com/1999-4915/15/8/1756 |
| work_keys_str_mv | AT kristinwidyasari effectivenessofbivalentomicroncontainingboostervaccinesagainstsarscov2omicronvariantamongindividualswithandwithoutpriorsarscov2infection AT jieunjang effectivenessofbivalentomicroncontainingboostervaccinesagainstsarscov2omicronvariantamongindividualswithandwithoutpriorsarscov2infection AT taejoonkang effectivenessofbivalentomicroncontainingboostervaccinesagainstsarscov2omicronvariantamongindividualswithandwithoutpriorsarscov2infection AT sunjookim effectivenessofbivalentomicroncontainingboostervaccinesagainstsarscov2omicronvariantamongindividualswithandwithoutpriorsarscov2infection |